Navigation Links
Hospira Reports Fourth-Quarter and Full-Year 2012 Results
Date:2/13/2013

LAKE FOREST, Ill., Feb. 13, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today reported results for the fourth quarter and full year ended Dec. 31, 2012. For the fourth quarter of 2012, net sales were $1.1 billion, and adjusted* diluted earnings per share were $0.55. (Adjusted* measures are adjusted for certain specified items as described later in this press release and the attached schedules.) On a U.S. Generally Accepted Accounting Principles (GAAP) basis, fourth-quarter 2012 diluted earnings per share were $0.03. For full-year 2012, net sales were $4.1 billion, and adjusted* diluted earnings per share were $2.01. On a GAAP basis, full-year 2012 diluted earnings per share were $0.27.

"The fourth quarter concluded a year of significant effort and advancement for Hospira," said F. Michael Ball, chief executive officer. "We made considerable progress on our quality transformation; we advanced our growth initiatives; and we met our financial projections. As we head into 2013, we remain committed to reinforcing our foundation, an area of key focus for the company.  We will continue to advance our remediation activities as well as work to increase supply of the products our customers -- and their patients -- depend on. At the same time, we are forging ahead with our growth expansion initiatives. Our efforts on both of these fronts serve to position Hospira for a stronger future of sustainable, long-term growth -- and to drive greater value for our customers and shareholders."

Fourth-Quarter 2012 ResultsThe following table highlights selected financial results for the fourth quarter of 2012 compared to the same period in 2011:In $ millions,

except per share

amounts

GAAP

Three Months Ended

Dec. 31,

%

Change

Adjusted*

<
'/>"/>
SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Hospira to Present at Upcoming Investor Conferences
2. Hospira and Q Core Medical Sign International Distribution Agreement for Sapphire Infusion System
3. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
4. Hospira Reports Third-Quarter 2012 Results
5. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
6. Hospira Reports Second-Quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira to Host Conference Call for Second-quarter 2012 Results
9. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
10. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
11. Hospira to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... JUPITER, Fla. , Oct. 1, 2014 /PRNewswire/ ... biotechnology company with patented and proprietary technology used ... for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial ... $500,000 licensing payment from Abengoa Bioenergy for commercial ... for converting biomass into ethanol, developed under Abengoa,s ...
(Date:10/1/2014)... , Oct. 1, 2014 Trovagene, ... diagnostics, announced today that Eli Diamond , ... Cancer Center (MSK), presented clinical data from an ... cancer monitoring platform for the determination of oncogene ... liquid biopsy.  The results were presented to both ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal Philips ... today announced its eCareCoordinator and eCareCompanion telehealth applications ... and Drug Administration (FDA). A part of Philips ... , eCareCoordinator and eCareCompanion are focused on patient ... clinical applications to be available through the cloud-based ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
... (Nasdaq: BIOD ) announced today that the ... development programs have been accepted for poster presentation at ... November 11 and 12, 2010: "Characterization of ... presented by Dr. Frank Flacke, November 12 ...
... -- WuXi PharmaTech (NYSE: WX ), ... and development outsourcing company with operations in China ... had been awarded a Certificate of Good Laboratory ... Drug Administration (SFDA), China,s regulatory authority for pharmaceuticals, ...
Cached Medicine Technology:Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting 2Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting 3Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting 4WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility 2
(Date:10/1/2014)... (PRWEB) October 01, 2014 Lifeinsurance-policy.com ... find the best life insurance prices for smokers. , ... life insurance premiums. Comparing quotes is the best method ... finding quotes for customers who need coverage. , ... entire duration of the policy. Since the coverage is ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
(Date:10/1/2014)... 2014 Farmington Company today announced ... mission and visual identity helping brokers, consultants and ... them to create greater benefit communication synergies. They ... on empowering customers to better leverage Farmington Company’s ... jewel of the rebrand is the refreshed tagline: ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... Between 23 million and 50 million people suffer ... from the National Institutes of Health (NIH) and the ... them have something else in common: They have a ... Gluten Free Therapeutics, makers of CeliVites nutritional supplements, ... publishing a series of blog posts aimed at educating ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... October is Breast Cancer Awareness,Month, and while awareness ... an,all-time high, the percentage of women receiving regular ... Disease Control and,Prevention. Women should know that emerging ... maintain their long-term breast health. Listen to ...
... blood leaving the liver during chemotherapy could prolong the lives ... procedure allows massive doses of chemotherapy drugs to reach the ... of the body. , The regime involves injecting the drug ... divert the blood leaving it. This blood is then filtered ...
... Germany, Sept. 26 Ziehm,Imaging, a provider ... a manufacturer of software-driven systems for targeted,less-invasive ... agreement for the integration of mobile 3D ... 2002, Ziehm Imaging and BrainLAB jointly pioneered ...
... Small Disadvantaged ... Businesses, ... and GlaxoSmithKline (NYSE: GSK ) today announced,the results of a ... disadvantaged businesses (SDBs). Rep. Kendrick B. Meek (D-Fla.), chairman of ...
... at ADA,s Annual,Meeting Here, SAN FRANCISCO, Sept. 26 ... including heart,problems, diabetes and pneumonia make it even more ... a lifetime., According to a recent report from ... keeping their natural teeth longer well beyond,the age of ...
... BIRMINGHAM, Ala., Sept. 26 HealthSouth,Corporation (NYSE: HLS ... a regular quarterly dividend of $16.25 per share on ... October 15,2007, to holders of record on October 1, ... largest provider of inpatient,rehabilitation services. Operating in 27 states ...
Cached Medicine News:Health News:'Re-plumbing' liver helps beat cancer 2Health News:Revision: Ziehm Imaging and BrainLAB Announce Partnership for Intra-Operative 3D Imaging and Computer Assisted Surgery (CAS) 2Health News:Revision: Ziehm Imaging and BrainLAB Announce Partnership for Intra-Operative 3D Imaging and Computer Assisted Surgery (CAS) 3Health News:Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results 2Health News:Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results 3Health News:OralLongevity (TM) Program Targets Oral Health of Older Americans 2Health News:OralLongevity (TM) Program Targets Oral Health of Older Americans 3Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2
... 1400 Series Biosafety Cabinets ... revolutionize working in a ... most comfortable, quiet, and ... cabinet on the market, ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
... Your patient will be more comfortable, ... tracheostomy tube stabilization more secure and to ... tying and untying of twill ties, consider ... adult and neonate/infant sizes, the narrow fastener ...
... Designed for ease of use and ... has smooth edges for comfort and is ... one-size-fits-all to a perfect fit. For hard ... a trach collar to your specifications. Don't ...
Medicine Products: